Compare US Global Jets ETF (JETS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Mesoblast Limited — how do they compare? US Global Jets ETF trades at $27.09 (market cap $878.48M), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and US Global Jets ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and Mesoblast Limited for 14 Days on average.
| JETS | MESO | |
|---|---|---|
Market Cap | $878.48M | $1.75B |
Volume | 4,465,925 | 239,027 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $20.96 |
52-Week Low | $23.64 | $13.19 |
Typical Hold Time | 26 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS (U.S. Global Jets ETF) trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent news highlights competitive pressure from defense-focused aerospace ETFs that have outperformed JETS on total returns.
The outlook remains challenging with fuel cost volatility and competitive ETF alternatives presenting risks. However, oversold technical conditions and potential travel demand recovery offer selective opportunities for investors seeking airline exposure. Key catalysts include fuel price stabilization and holiday travel trends.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
